These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 10656461

  • 1. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.
    Kraus-Berthier L, Jan M, Guilbaud N, Naze M, Pierré A, Atassi G.
    Clin Cancer Res; 2000 Jan; 6(1):297-304. PubMed ID: 10656461
    [Abstract] [Full Text] [Related]

  • 2. Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
    Feng F, Wang B, Sun X, Zhu Y, Tang H, Nan G, Wang L, Wu B, Huhe M, Liu S, Diao T, Hou R, Zhang Y, Zhang Z.
    Cancer Biol Ther; 2017 Jan 02; 18(1):51-62. PubMed ID: 28055291
    [Abstract] [Full Text] [Related]

  • 3. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.
    Health Technol Assess; 2001 Jan 02; 5(32):1-195. PubMed ID: 12065068
    [Abstract] [Full Text] [Related]

  • 4. Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer.
    Zhao Y, Wang Z, Shi X, Liu T, Yu W, Ren X, Zhao H.
    Technol Cancer Res Treat; 2023 Jan 02; 22():15330338231202307. PubMed ID: 37728201
    [Abstract] [Full Text] [Related]

  • 5. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
    Bunn PA, Kelly K.
    Clin Cancer Res; 1998 May 02; 4(5):1087-100. PubMed ID: 9607565
    [Abstract] [Full Text] [Related]

  • 6. Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment.
    Meert AP, Berghmans T, Branle F, Lemaître F, Mascaux C, Rubesova E, Vermylen P, Paesmans M, Sculier JP.
    Anticancer Res; 1999 May 02; 19(5C):4379-90. PubMed ID: 10650780
    [Abstract] [Full Text] [Related]

  • 7. Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
    Hanada M, Noguchi T, Yamaoka T.
    Cancer Sci; 2007 Mar 02; 98(3):447-54. PubMed ID: 17214744
    [Abstract] [Full Text] [Related]

  • 8. [Maintenance chemotherapy in advanced NSCLC].
    Krazkowski M.
    Rev Pneumol Clin; 2006 Feb 02; 62 Spec no 1():1S16-8. PubMed ID: 16719150
    [No Abstract] [Full Text] [Related]

  • 9. Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non-small-cell lung cancer cells.
    Zhang M, Boyer M, Rivory L, Hong A, Clarke S, Stevens G, Fife K.
    Int J Radiat Oncol Biol Phys; 2004 Feb 01; 58(2):353-60. PubMed ID: 14751503
    [Abstract] [Full Text] [Related]

  • 10. Chemotherapy for non-small cell lung cancer: have we reached a new plateau?
    Shepherd FA.
    Semin Oncol; 1999 Feb 01; 26(1 Suppl 4):3-11. PubMed ID: 10201515
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
    Kraus-Berthier L, Guilbaud N, Léonce S, Parker T, Genissel P, Guillonneau C, Goldstein S, Atassi G, Pierré A.
    Cancer Chemother Pharmacol; 2002 Aug 01; 50(2):95-103. PubMed ID: 12172972
    [Abstract] [Full Text] [Related]

  • 12. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).
    Thomas P, Robinet G, Gouva S, Fournel P, Léna H, Le Caer H, Perol M, Berard H, Bombaron P, Vergnenegre A, Kleisbauer JP, Groupe français de pneumo-cancérologie.
    Lung Cancer; 2006 Jan 01; 51(1):105-14. PubMed ID: 16310886
    [Abstract] [Full Text] [Related]

  • 13. Rationale for non-platinum chemotherapy in advanced NSCLC.
    Murren JR.
    Oncology (Williston Park); 2001 Jul 01; 15(7 Suppl 8):29-34. PubMed ID: 11497229
    [Abstract] [Full Text] [Related]

  • 14. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
    Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M, Visalli M, Bisagni E, Pierré A, Atassi G.
    Cancer Chemother Pharmacol; 1996 Jul 01; 38(6):513-21. PubMed ID: 8823492
    [Abstract] [Full Text] [Related]

  • 15. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
    Ferrigno D, Buccheri G.
    Lung Cancer; 2000 Aug 01; 29(2):91-104. PubMed ID: 10963840
    [Abstract] [Full Text] [Related]

  • 16. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
    Han JY, Lee DH, Song JE, Lee SY, Kim HY, Kim HT, Lee JS.
    Cancer; 2008 Jul 15; 113(2):388-95. PubMed ID: 18484595
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study.
    Dongiovanni D, Fissore C, Berruti A, Buffoni L, Addeo A, Barone C, Polimeni MA, Ottaviani D, Bertetto O, Dongiovanni V.
    Lung Cancer; 2005 Feb 15; 47(2):269-75. PubMed ID: 15639726
    [Abstract] [Full Text] [Related]

  • 19. A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
    Argiris A, Liptay M, LaCombe M, Marymont M, Kies MS, Sundaresan S, Masters G.
    Lung Cancer; 2004 Aug 15; 45(2):243-53. PubMed ID: 15246197
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
    Lee DH, Han JY, Cho KH, Pyo HR, Kim HY, Yoon SJ, Lee JS.
    Int J Radiat Oncol Biol Phys; 2005 Nov 15; 63(4):1037-44. PubMed ID: 16024178
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.